S&P 5005,963+0.54%
NASDAQ21,443+0.87%
DOW43,892+0.31%
DAX23,888+0.44%
FTSE 1008,721-0.12%
EUR/USD1.1465+0.07%
GBP/USD1.3220+0.14%
USD/JPY161.31-0.03%
Gold3,241+0.22%
WTI Oil76.40+0.81%
Bitcoin103,241+1.43%
10Y UST4.47%-9bp
S&P 5005,963+0.54%
NASDAQ21,443+0.87%
DOW43,892+0.31%
DAX23,888+0.44%
FTSE 1008,721-0.12%
EUR/USD1.1465+0.07%
GBP/USD1.3220+0.14%
USD/JPY161.31-0.03%
Gold3,241+0.22%
WTI Oil76.40+0.81%
Bitcoin103,241+1.43%
10Y UST4.47%-9bp
MarketsFN
Home/Hedge Funds/Darwin Global Management/Q2 2024

Darwin Global Management

Period: Q2 2024 Β· Filed: 2024-08-14
View on SEC EDGAR β†—
AUM
$860M
Total portfolio value
Positions
9
Reported securities
Top Holding
CYTK
28.6% $246.1M
QoQ Changes
+5 / -8
new Β· exited
⚠️13F Filing Disclosure

AUM figures shown are calculated by summing the reported market value of all positions in SEC 13F-HR filings β€” not the fund's actual assets under management.

  • Excludes cash, bonds, private equity, short positions, and foreign-listed stocks not required to be reported.
  • For PUT and CALL options, the reported Value is the notional value of the underlying shares β€” not the option premium paid. This significantly overstates the actual capital at risk.
  • Actual fund AUM is typically higher and includes strategies, instruments, and positions that never appear in a 13F.
  • 13F filings cover institutional managers with β‰₯$100M in 13F securities. Positions reflect end-of-quarter holdings, disclosed up to 45 days after the period ends.

Data sourced from SEC EDGAR. This tracker is for informational purposes only and does not constitute investment advice.

Portfolio Holdings

Top 9 positions

⚠️ Performance % calculated from filing date ( 2024-08-14) shown is the underlying stock price movement β€” not the derivative's P&L.
TickerIssuerNotionalPort %@ FilingNow (EOD)Since FilingAllocation
CYTKCYTOKINETICS INC$246.1M28.63%$54.70$86.49+58.1%
28.6%
INSMINSMED INC$237.1M27.58%$66.34$111.60+68.2%
27.6%
PCVXVAXCYTE INC$163.9M19.07%$76.94$58.39-24.1%
19.1%
GERNGERON CORP$106.2M12.35%$4.34$1.36-68.7%
12.3%
KROSKEROS THERAPEUTICS INC$68.8M8.00%$43.77$11.26-74.3%
8.0%
CRBPCORBUS PHARMACEUTICALS HLDGS$14.3M1.66%$49.40$9.25-81.3%
1.7%
SYRESPYRE THERAPEUTICS INC$10.3M1.19%$24.55$86.63+252.9%
1.2%
RNAMAVIDITY BIOSCIENCES INC$8.1M0.94%β€”β€”
0.9%
ELEVELEVATION ONCOLOGY INC$4.8M0.56%β€”β€”
0.6%

Quarter-on-Quarter Activity

Q2 2024 vs. Q1 2024

New Positions (5)

TickerIssuerNotionalSince Filing
CYTKCYTOKINETICS INC$246.1M+58.1%
INSMINSMED INC$237.1M+68.2%
GERNGERON CORP$106.2M-68.7%
CRBPCORBUS PHARMACEUTICALS HLDGS$14.3M-81.3%
RNAMAVIDITY BIOSCIENCES INC$8.1M

Exited Positions (8)

TickerIssuerNotional
NUVLNUVALENT INC$107.9M
BHVNBIOHAVEN LTD$80.8M
ALPNALPINE IMMUNE SCIENCES INC$78.6M
BEAMBEAM THERAPEUTICS INC$70.0M
APGEAPOGEE THERAPEUTICS INC$55.3M
XNCRXENCOR INC$24.6M
TRMLTOURMALINE BIO INC$10.7M
MRKMERCK & CO INC$10.5M

Increased (1)

TickerIssuerNotionalShares Ξ”Since Filing
KROSKEROS THERAPEUTICS INC$-26.3M+6.3%-74.3%

Trimmed (3)

TickerIssuerNotionalShares Ξ”Since Filing
PCVXVAXCYTE INC$-24.0M-24.4%-24.1%
ELEVELEVATION ONCOLOGY INC$-7.2M-17.9%
SYRESPYRE THERAPEUTICS INC$-7.7M-4.5%+252.9%
← Back to Hedge Funds